TrialJCI insight2021

Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients.

Max M Wattenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.